Endocrine Abstracts

Background: Ghrelin was recently discovered as the natural ligand for the G protein-coupled growth hormone secretagogue receptor and induces GH release through GHS-R1a. The octanoylation of its third serine residue is responsible for GH release and receptor binding. A variant of ghrelin devoid of this modification, desoctanoyl-ghrelin, can neither bind to the receptor nor induce GH release. Ghrelin has also been shown to effect cellular proliferation, being pro-proliferative i...

Sporadic pituitary tumours are generally benign tumours in which the none of the oncogenes or tumour suppressor genes classically mutated in other cancers are commonly mutated, nor are there frequent changes in genes associated with genetic endocrine neoplasia syndromes. Such tumours are associated with excessive but not completely unregulated proliferation, implicating a possible abnormality in a cell signalling pathway in their pathogenesis. Recently, the serine/threonine ki...

It has been reported that both normal pituitary and pituitary tumours express PPAR gamma, a nuclear hormone receptor, the expression being much more abundant in pituitary tumours. It has also been suggested that PPAR gamma agonists, such as the thiazolidenediones, could be used as a therapeutic option for pituitary tumours. In order to investigate this further, 'Real time' PCR was used to assess PPAR gamma RNA expression, and Western blotting and immunohistochemistry was used ...